1. Home
  2. TTI vs NRIX Comparison

TTI vs NRIX Comparison

Compare TTI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tetra Technologies Inc.

TTI

Tetra Technologies Inc.

HOLD

Current Price

$8.10

Market Cap

1.5B

Sector

Energy

ML Signal

HOLD

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$15.07

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTI
NRIX
Founded
1981
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.7B
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
TTI
NRIX
Price
$8.10
$15.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
13
Target Price
$10.40
$29.46
AVG Volume (30 Days)
1.8M
706.3K
Earning Date
05-28-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
N/A
$76,987,000.00
Revenue This Year
$4.17
N/A
Revenue Next Year
$10.41
$26.32
P/E Ratio
$418.50
N/A
Revenue Growth
N/A
99.31
52 Week Low
$2.03
$8.18
52 Week High
$12.54
$22.50

Technical Indicators

Market Signals
Indicator
TTI
NRIX
Relative Strength Index (RSI) 29.29 37.80
Support Level $6.88 $11.34
Resistance Level $8.27 $16.49
Average True Range (ATR) 0.54 0.76
MACD -0.32 0.02
Stochastic Oscillator 0.59 24.87

Price Performance

Historical Comparison
TTI
NRIX

About TTI Tetra Technologies Inc.

Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments namely Completion Fluids & Products, and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. Majority of revenue is from Completion Fluids & Products. The company derives maximum revenue from United states.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Share on Social Networks: